Skip to main content
OpenTrials

Clinical trial condition

Recurrent Hodgkin Lymphoma

Explore clinical trials studying Recurrent Hodgkin Lymphoma. Study availability and eligibility vary by location and protocol.

28 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Hodgkin Lymphoma trial results

Completed

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT02824029

Conditions
Classical Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +9 more
Locations
  • University of Michigan Health System Ann Arbor, Michigan, United States
  • Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States
  • University of Tennessee Knoxville, Tennessee, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Completed

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

NCT02869633

Conditions
Blastoid Variant Mantle Cell Lymphoma, Chronic Disease, Disease Attributes, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Stanford Cancer Institute Palo Alto, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
View Trial Details
Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

NCT02304458

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +53 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
View all 25 locations
View Trial Details
Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

NCT01822509

Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Blood Protein Disorders, Bone Marrow Diseases, +44 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 13 locations
View Trial Details
Completed

Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant

NCT00068718

Conditions
Blast Crisis, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blood Protein Disorders, +38 more
Locations
  • VA Puget Sound Health Care System Seattle, Washington, United States
  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
  • Universitaet Leipzig Leipzig, Germany
  • University of Torino Torino, Italy
View Trial Details

Related conditions